SVRAMEDIUM SIGNALFINANCIAL10-K

SVRA's annual filing shows deteriorating operational performance with meaningfully higher losses and cash burn despite maintaining a strong balance sheet position.

The company's core operational metrics moved in the wrong direction, with net losses expanding and operating cash outflows increasing by over 13%, indicating mounting pressure on the business model. However, the company maintains substantial liquidity with current assets of $241.6M and a strong equity base, providing financial runway to execute its strategy.

Comparing 2026-03-13 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

SVRA's financial position presents a mixed picture with concerning operational trends offset by balance sheet strength. The company saw net losses expand meaningfully to $118.8M while operating cash burn increased to $101.0M, signaling mounting operational challenges. However, the balance sheet remained robust with total assets growing 19.1% to $253.4M and stockholders' equity increasing 18.5% to $203.1M, suggesting adequate financial resources despite the operational headwinds.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-45.5%
$2.1M→$1.2M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Liabilities
Balance Sheet
+38.5%
$14.7M→$20.4M

Current liabilities surged 38.5% — significant near-term obligations; verify ability to meet short-term debt.

Net Income
P&L
-23.9%
-$95.9M→-$118.8M

Net income declined 23.9% — review whether driven by operations, interest costs, or non-recurring items.

Total Liabilities
Balance Sheet
+21.4%
$41.4M→$50.3M

Liabilities increased 21.4% — monitor debt-to-equity ratio and interest coverage.

Operating Income
P&L
-19.7%
-$103.2M→-$123.5M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Current Assets
Balance Sheet
+19.5%
$202.1M→$241.6M

Current assets grew 19.5% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+19.1%
$212.9M→$253.4M

Asset base grew 19.1% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
+18.5%
$171.4M→$203.1M

Equity base grew 18.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

SG&A Expense
P&L
-14.8%
$11.0M→$9.3M

SG&A reduced 14.8% — improved cost efficiency or headcount reduction improving operating margins.

Operating Cash Flow
Cash Flow
-13.4%
-$89.1M→-$101.0M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-03-13
PRIOR — 2025-03-27
ADDED
1 Summary Risk Factors An investment in our securities involves significant risks.
Below is a summary of some of the material risks associated with our business and investment in our securities.
It should be read together with the text of the full risk factors below in Item 1A.
Risk Factors and the other information set forth in this annual report on Form 10-K, including our financial statements and the related notes, as well as in other documents that we file with the U.S.
We are substantially dependent upon the clinical, regulatory, and commercial success of our sole product candidate, molgramostim inhalation solution ("MOLBREEVI" or molgramostim ).
+7 more — sign up free →
REMOVED
Risks Related to Development and Commercialization of our Product Candidate We are substantially dependent upon the clinical, regulatory, and commercial success of our sole product candidate, molgramostim inhaled solution ("MOLBREEVI").
Even if we receive regulatory approval for our product candidate, we may face regulatory difficulties that could materially and adversely affect our business, financial condition, and results of operations.
Risks Related to Our Capital Requirements and Financial Condition We have incurred significant losses since inception and expect that we will continue to incur losses for the foreseeable future, which makes it difficult to assess our future viability.
We may require additional financing to obtain regulatory approval for MOLBREEVI and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our product development efforts or other operations.
Any future acquisitions that we make could disrupt our business and harm our financial condition.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →